Home โบ Myelofibrosis
Myelofibrosis clinical trials recruiting in the U.S.
56 studies for Myelofibrosis are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX19 studies
- New York City, NY18 studies
- Durham, NC12 studies
- Boston, MA12 studies
- Columbus, OH11 studies
- Seattle, WA11 studies
- Salt Lake City, UT10 studies
- Miami, FL10 studies
- Cleveland, OH9 studies
- Tampa, FL9 studies
- Atlanta, GA9 studies
- Nashville, TN9 studies
- Baldwin Park, CA9 studies
- St. Louis, MO8 studies
- Ann Arbor, MI8 studies
- Chicago, IL7 studies
- Birmingham, AL7 studies
- Baltimore, MD7 studies
- Mountain View, CA7 studies
- Los Angeles, CA6 studies
- Philadelphia, PA6 studies
- Winston-Salem, NC6 studies
- Irvine, CA5 studies
- Kansas City, MO5 studies
- Portland, OR5 studies
- Cincinnati, OH5 studies
- Dallas, TX5 studies
- Milwaukee, WI4 studies
- Charlotte, NC4 studies
- New Haven, CT4 studies
- Denver, CO4 studies
- Minneapolis, MN4 studies
- Washington, DC4 studies
- Jacksonville, FL4 studies
- Edison, NJ4 studies
- Sacramento, CA3 studies
- The Bronx, NY3 studies
- Coral Springs, FL3 studies
- Orange, CA3 studies
- Charleston, SC3 studies
By state
- Alabama7 studies
- Arizona7 studies
- California21 studies
- Colorado6 studies
- Connecticut5 studies
- Florida14 studies
- Georgia9 studies
- Illinois7 studies
- Kansas6 studies
- Maryland9 studies
- Massachusetts13 studies
- Michigan10 studies
- Minnesota7 studies
- Missouri8 studies
- New Jersey6 studies
- New York21 studies
- North Carolina17 studies
- Ohio17 studies
- Oregon6 studies
- Pennsylvania8 studies
- South Carolina4 studies
- Tennessee9 studies
- Texas20 studies
- Utah10 studies
- Virginia5 studies
- Washington11 studies
- Wisconsin5 studies
Recently updated studies
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Oct 2, 2026 ยท NCT04176198A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Oct 2, 2026 ยท NCT07357727A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 1, 2026 ยท NCT07469891Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 1, 2026 ยท NCT07521046A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Oct 1, 2026 ยท NCT07623161A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 30, 2026 ยท NCT06661915Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RecruitingEarly phase 1
Ages 18 and older ยท All sexes ยท Updated Sep 24, 2026 ยท NCT06398457Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Sep 23, 2026 ยท NCT05320198Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 17, 2026 ยท NCT04282187A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 17, 2026 ยท NCT06343805High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
RecruitingPhase 2
Ages 18 to 75 ยท All sexes ยท Updated Sep 16, 2026 ยท NCT06345495Pacritinib Effectiveness in Real-world Settings
RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Sep 14, 2026 ยท NCT07774455A Telehealth Advance Care Planning Intervention
Recruiting
Ages 60 and older ยท All sexes ยท Updated Sep 11, 2026 ยท NCT05875805Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RecruitingPhase 2
Ages 18 to 75 ยท All sexes ยท Updated Aug 19, 2026 ยท NCT07228624TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
RecruitingPhase 1
Ages 18 to 80 ยท All sexes ยท Updated Aug 17, 2026 ยท NCT07302776A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Aug 6, 2026 ยท NCT07008118Quantitative MRI for Myelofibrosis
RecruitingObservational study
Ages 18 to 99 ยท All sexes ยท Updated Jul 31, 2026 ยท NCT01973881A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Jul 28, 2026 ยท NCT06773195A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 75 ยท All sexes ยท Updated Jul 28, 2026 ยท NCT07020533Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Jul 22, 2026 ยท NCT07441694A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Jul 20, 2026 ยท NCT07250646Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RecruitingPhase 2
Ages 18 to 70 ยท All sexes ยท Updated Jul 20, 2026 ยท NCT04370301Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Jul 15, 2026 ยท NCT07128381Allo HSCT Using RIC and PTCy for Hematological Diseases
RecruitingPhase 2
Up to age 75 ยท All sexes ยท Updated Jul 6, 2026 ยท NCT05805605Registry of Older Patients With Cancer
RecruitingObservational study
Ages 65 and older ยท All sexes ยท Updated Jun 29, 2026 ยท NCT01137825From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.